Best Antidepressant for Glaucoma Patients
For patients with open-angle glaucoma requiring antidepressant therapy, selective serotonin reuptake inhibitors (SSRIs) are the safest first-line choice, as they are not associated with increased glaucoma risk and may actually lower intraocular pressure. 1, 2
Primary Recommendation: SSRIs
SSRIs demonstrate no association with increased glaucoma risk across multiple case-control studies (pooled adjusted OR = 0.956,95% CI = 0.807-1.133, p = 0.604), making them the preferred antidepressant class for glaucoma patients 2
SSRIs may actually lower intraocular pressure compared to non-users (Hedges' g = -0.519,95% CI = -0.743 to -0.296, p < 0.001), providing a potential protective effect 2
The American Academy of Ophthalmology confirms that anticholinergic antidepressants are less problematic in open-angle glaucoma compared to angle-closure glaucoma, but SSRIs remain the safest option 1
Antidepressants to Avoid or Use With Extreme Caution
Tricyclic Antidepressants (TCAs)
TCAs should be avoided in glaucoma patients due to their anticholinergic properties and association with increased cataract risk (ROR = 1.31-12.81) 3, 4
TCAs carry particular risk in angle-closure glaucoma through mydriasis-induced pupillary block, though this mechanism is less relevant in open-angle disease 5, 6
Bupropion is specifically contraindicated in closed-angle glaucoma according to manufacturer labeling and NCCN guidelines 7
Other High-Risk Agents
Benzodiazepines should be used with caution in glaucoma patients, particularly those with narrow angles 4
Tetracyclic antidepressants (TeCAs) and MAOIs show variable associations with ocular complications and require careful monitoring 3
Alternative Safe Options
SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)
SNRIs are well-evidenced as having no association with glaucoma and represent a safe alternative to SSRIs 4
SNRIs may also lower intraocular pressure similar to SSRIs, based on pooled antidepressant data 2
Critical Management Considerations
For Open-Angle Glaucoma Specifically
Patients with open-angle glaucoma can proceed with SSRIs or SNRIs without significant concern for worsening glaucoma, as recommended by the American Academy of Ophthalmology 1
Continue prostaglandin analog therapy (first-line glaucoma treatment) concurrently with antidepressant therapy to maintain IOP control 8, 1
Monitoring Requirements
Maintain regular ophthalmologic follow-up to monitor intraocular pressure and optic nerve status, as nearly 45% of glaucoma patients demonstrate poor medication adherence 1
Reassess IOP 2-4 weeks after initiating antidepressant therapy to verify no adverse pressure changes, particularly if using agents other than SSRIs/SNRIs 8
Angle-Closure vs. Open-Angle Distinction
The type of glaucoma fundamentally determines antidepressant safety: anticholinergic agents pose significant risk in angle-closure glaucoma through pupillary dilation and angle narrowing, but this mechanism is not operative in open-angle disease 5, 1
For angle-closure glaucoma or suspects, SSRIs carry a 5.80-fold increased risk of acute angle-closure attacks (95% CI 1.89-17.9), with risk increasing to 8.53-fold at doses exceeding 20 mg daily 9
This angle-closure risk does NOT apply to open-angle glaucoma patients, where SSRIs remain safe 1, 2
Common Pitfalls to Avoid
Do not assume all antidepressants carry equal glaucoma risk—the evidence clearly distinguishes SSRIs/SNRIs as safe from TCAs as problematic 3, 4, 2
Do not withhold necessary antidepressant therapy in open-angle glaucoma patients due to unfounded concerns, as SSRIs are safe and depression itself impairs glaucoma medication adherence 1, 2
Do not prescribe TCAs or bupropion without confirming the patient has open-angle (not closed-angle) glaucoma and is under active ophthalmologic care 7, 5
Do not overlook systemic anticholinergic medications from other specialists (antihistamines, antispasmodics, antiparkinsonian agents) that may compound risk when combined with anticholinergic antidepressants 5